article thumbnail

Expert view: What’s next for cell and gene therapy?

Drug Discovery World

What are the global innovations in cell and gene therapy? Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources.

article thumbnail

What challenges does the advanced therapies sector face? 

Drug Discovery World

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Changing Faces: pharma supplier, DTx, and non-profit hires from November 2022

pharmaphorum

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Reagents supplier The Native Antigen Company has hired a new business development manager, Richard White , and senior product manager, Pardeep Sharda.

article thumbnail

GenScript expands capacity for cell and gene therapy programmes

Drug Discovery World

GenScript USA has expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. . The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7